Lessons from SARS‑CoV‑2 and its variants (Review)
- Authors:
- Ziwen Qin
- Yan Sun
- Jian Zhang
- Ling Zhou
- Yujuan Chen
- Chuanjun Huang
-
Affiliations: The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250013, P.R. China, Department of Respiratory Diseases, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China, Department of Respiratory Diseases, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250013, P.R. China - Published online on: June 22, 2022 https://doi.org/10.3892/mmr.2022.12779
- Article Number: 263
-
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Scott L, Hsiao NY, Moyo S, Singh L, Tegally H, Dor G, Maes P, Pybus OG, Kraemer MUG, Semenova E, et al: Track omicron's spread with molecular data. Science. 374:1454–1455. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Dyer O: Covid-19: South Africa's surge in cases deepens alarm over omicron variant. BMJ. 375:n30132021. View Article : Google Scholar : PubMed/NCBI | |
|
Callaway E and Ledford H: How bad is Omicron? What scientists know so far. Nature. 600:197–199. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, Tambone V, Caruso A, Angeletti S, Zella D and Ciccozzi M: Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun. 538:88–91. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L and Wang X: Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 581:215–220. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Liu Q and Guo D: Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 92:418–423. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L, Nakane T, Zivanov J, Neufeldt CJ, Cerikan B and Lu JM: Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature. 588:498–502. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS and Manson JJ; HLH Across Speciality Collaboration UK, : COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 395:1033–1034. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Thacker VV, Sharma K, Dhar N, Mancini GF, Sordet-Dessimoz J and McKinney JD: Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model. EMBO Rep. 22:e527442021. View Article : Google Scholar : PubMed/NCBI | |
|
Batah SS and Fabro AT: Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir Med. 176:1062392021. View Article : Google Scholar : PubMed/NCBI | |
|
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, et al: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 315:788–800. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A; COVID-19 Genomics UK (COG-UK) Consortium, ; et al: SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 19:409–424. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X, Mao Q, Xu M and Liang Z: Impact of the delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines. 20:1201–1209. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sternberg A and Naujokat C: Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sci. 257:1180562020. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, et al: The omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 185:447–456.e11. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT and Kim SJ: Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 30:313–324. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shiehzadegan S, Alaghemand N, Fox M and Venketaraman V: Analysis of the delta variant B.1.617.2 COVID-19. Clin Pract. 11:778–784. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, Lorson CL, Byrareddy SN and Singh K: Evolutionary analysis of the delta and delta plus variants of the SARS-CoV-2 viruses. J Autoimmun. 124:1027152021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Wang R, Gilby NB and Wei GW: Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 62:412–422. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Yin XG, Wen Y, Lu J, Zhang RY, Zhou SH, Liao CM, Wei HW and Guo J: MPLA-adjuvanted liposomes encapsulating S-trimer or RBD or S1, but not S-ECD, elicit robust neutralization against SARS-CoV-2 and variants of concern. J Med Chem. 65:3563–3574. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Meo SA, Meo AS, Al-Jassir FF and Klonoff DC: Omicron SARS-CoV-2 new variant: Global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 25:8012–8018. 2021.PubMed/NCBI | |
|
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 395:507–513. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, et al: A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: An international collaborative group. Oncologist. 25:e936–e945. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, et al: Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy region, Italy. JAMA. 323:1574–1581. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Halpin DMG, Faner R, Sibila O, Badia JR and Agusti A: Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 8:436–438. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Luo C, Yao L, Zhang L, Yao M, Chen X, Wang Q and Shen H: Possible transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a public bath center in Huai'an, Jiangsu Province, China. JAMA Netw Open. 3:e2045832020. View Article : Google Scholar : PubMed/NCBI | |
|
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, et al: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 395:514–523. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kampf G, Todt D, Pfaender S and Steinmann E: Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 104:246–251. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, Stepp HE and Clements TP: A guide to COVID-19: A global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 287:3633–3650. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jayaweera M, Perera H, Gunawardana B and Manatunge J: Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ Res. 188:1098192020. View Article : Google Scholar : PubMed/NCBI | |
|
Morawska L and Cao J: Airborne transmission of SARS-CoV-2: The world should face the reality. Environ Int. 139:1057302020. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S and Ma K: A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 54:12–16. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira LJ, Pereira CV, Murata RM, Pardi V and Pereira-Dourado SM: Biological and social aspects of coronavirus disease 2019 (COVID-19) related to oral health. Braz Oral Res. 34:e0412020. View Article : Google Scholar : PubMed/NCBI | |
|
Jackson CB, Farzan M, Chen B and Choe H: Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 23:3–20. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Meyerowitz EA, Richterman A, Gandhi RT and Sax PE: Transmission of SARS-CoV-2: A review of viral, host, and environmental factors. Ann Intern Med. 174:69–79. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wild PS, Dimmeler S and Eschenhagen T: An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations. J Mol Cell Cardiol. 141:108–109. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L and Wang M: Presumed asymptomatic carrier transmission of COVID-19. JAMA. 323:1406–1407. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Soetikno R, Teoh AYB, Kaltenbach T, Lau JYW, Asokkumar R, Cabral-Prodigalidad P and Shergill A: Considerations in performing endoscopy during the COVID-19 pandemic. Gastrointest Endosc. 92:176–183. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ludwig S and Zarbock A: Coronaviruses and SARS-CoV-2: A brief overview. Anesth Analg. 131:93–96. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Yang S, Xu Y, Qin X, Liu J, Guo J, Tian S, Wang S, Liao K, Zhang Y, et al: Epidemiological and clinical characteristics of imported cases of COVID-19: A multicenter study. BMC Infect Dis. 21:4062021. View Article : Google Scholar : PubMed/NCBI | |
|
Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, et al: Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: A cross-sectional study. Clin Infect Dis. 71:889–890. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako DG, et al: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 602:654–656. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wong RSY: The SARS-CoV-2 outbreak: An epidemiological and clinical perspective. SN Compr Clin Med. 2:1983–1991. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N and Esmaeilzadeh A: COVID-19: Virology, biology and novel laboratory diagnosis. J Gene Med. 23:e33032021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, et al: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 368:m10912020. View Article : Google Scholar : PubMed/NCBI | |
|
Fang X, Zhao M, Li S, Yang L and Wu B: Changes of CT findings in a 2019 novel coronavirus (2019-nCoV) pneumonia patient. QJM. 113:271–272. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
George PM, Wells AU and Jenkins RG: Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 8:807–815. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ma X, Liang M, Ding M, Liu W, Ma H, Zhou X and Ren H: Extracorporeal membrane oxygenation (ECMO) in critically Ill patients with coronavirus disease 2019 (COVID-19) pneumonia and acute respiratory distress syndrome (ARDS). Med Sci Monit. 26:e9253642020. View Article : Google Scholar : PubMed/NCBI | |
|
Baruah V and Bose S: Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 92:495–500. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sieker JT, Horowitz C, Hu CK, Lacombe-Daphnis M, Chirokas B, Pina C, Heger NE, Rabson AR, Zhou M, Bogen SA and Horowitz GL: Analytic sensitivity of 3 nucleic acid detection assays in diagnosis of SARS-CoV-2 infection. J Appl Lab Med. 6:421–428. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, et al: 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 397:220–232. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, Mukhopadhyay S, Stroberg E, Duval EJ, Barton LM and Hajj Hussein I: COVID-19: A multidisciplinary review. Front Public Health. 8:3832020. View Article : Google Scholar : PubMed/NCBI | |
|
Stang A, Robers J, Schonert B, Jöckel KH, Spelsberg A, Keil U and Cullen P: The performance of the SARS-CoV-2 RT-PCR test as a tool for detecting SARS-CoV-2 infection in the population. J Infect. 83:237–279. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Islam KU and Iqbal J: An update on molecular diagnostics for COVID-19. Front Cell Infect Microbiol. 10:5606162020. View Article : Google Scholar : PubMed/NCBI | |
|
Kucirka LM, Lauer SA, Laeyendecker O, Boon D and Lessler J: Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 173:262–267. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Harper H, Burridge A, Winfield M, Finn A, Davidson A, Matthews D, Hutchings S, Vipond B, Jain N; COVID-19 Genomics UK (COG-UK) Consortium, ; et al: Detecting SARS-CoV-2 variants with SNP genotyping. PLoS One. 16:e02431852021. View Article : Google Scholar : PubMed/NCBI | |
|
Stelzer-Braid S, Walker GJ, Aggarwal A, Isaacs SR, Yeang M, Naing Z, Ospina Stella A, Turville SG and Rawlinson WD: Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes. Pathology. 52:760–763. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kleiboeker S, Cowden S, Grantham J, Nutt J, Tyler A, Berg A and Altrich M: SARS-CoV-2 viral load assessment in respiratory samples. J Clin Virol. 129:1044392020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL and Zhou P: Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes. Emerg Microbes Infect. 9:386–389. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shen M, Zhou Y, Ye J, Abdullah Al-Maskri AA, Kang Y, Zeng S and Cai S: Recent advances and perspectives of nucleic acid detection for coronavirus. J Pharm Anal. 10:97–101. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bustin SA and Mueller R: Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond). 109:365–379. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, et al: Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect Dis. 20:565–574. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas E, Delabat S, Carattini YL and Andrews DM: SARS-CoV-2 and variant diagnostic testing approaches in the United States. Viruses. 13:24922021. View Article : Google Scholar : PubMed/NCBI | |
|
Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM and Jahanshahi-Anbuhi S: Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 34:e00228–20. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Augustine R, Hasan A, Das S, Ahmed R, Mori Y, Notomi T, Kevadiya BD and Thakor AS: Loop-mediated isothermal amplification (LAMP): A rapid, sensitive, specific, and cost-effective point-of-care test for coronaviruses in the context of COVID-19 pandemic. Biology (Basel). 9:1822020.PubMed/NCBI | |
|
Chau CH, Strope JD and Figg WD: COVID-19 clinical diagnostics and testing technology. Pharmacotherapy. 40:857–868. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Alcoba-Florez J, Gil-Campesino H, Artola DG, González-Montelongo R, Valenzuela-Fernández A, Ciuffreda L and Flores C: Sensitivity of different RT-qPCR solutions for SARS-CoV-2 detection. Int J Infect Dis. 99:190–192. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Giuliani C: The flavonoid quercetin induces AP-1 activation in FRTL-5 thyroid cells. Antioxidants (Basel). 8:1122019. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Z, Zhang Y, Wang Y, Huang Z and Song B: Chest CT manifestations of new coronavirus disease 2019 (COVID-19): A pictorial review. Eur Radiol. 30:4381–4389. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kanne JP: Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: Key points for the radiologist. Radiology. 295:16–17. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nivet H, Crombé A, Schuster P, Ayoub T, Pourriol L, Favard N, Chazot A, Alonzo-Lacroix F, Youssof E, Ben Cheikh A, et al: The accuracy of teleradiologists in diagnosing COVID-19 based on a French multicentric emergency cohort. Eur Radiol. 31:2833–2844. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ghose A, Roy S, Vasdev N, Olsburgh J and Dasgupta P: The emerging role of artificial intelligence in the fight against COVID-19. Eur Urol. 78:775–776. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ozsahin I, Sekeroglu B, Musa MS, Mustapha MT and Uzun Ozsahin D: Review on diagnosis of COVID-19 from chest CT images using artificial intelligence. Comput Math Methods Med. 2020:97565182020. View Article : Google Scholar : PubMed/NCBI | |
|
Shi F, Wang J, Shi J, Wu Z, Wang Q, Tang Z, He K, Shi Y and Shen D: Review of artificial intelligence techniques in imaging data acquisition, segmentation, and diagnosis for COVID-19. IEEE Rev Biomed Eng. 14:4–15. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bouchareb Y, Moradi Khaniabadi P, Al Kindi F, Al Dhuhli H, Shiri I, Zaidi H and Rahmim A: Artificial intelligence-driven assessment of radiological images for COVID-19. Comput Biol Med. 136:1046652021. View Article : Google Scholar : PubMed/NCBI | |
|
Vaishya R, Javaid M, Khan IH and Haleem A: Artificial intelligence (AI) applications for COVID-19 pandemic. Diabetes Metab Syndr. 14:337–339. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, Srouji S and Sela E: Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur J Epidemiol. 35:775–779. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mouffak S, Shubbar Q, Saleh E and El-Awady R: Recent advances in management of COVID-19: A review. Biomed Pharmacother. 143:1121072021. View Article : Google Scholar : PubMed/NCBI | |
|
Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG, Psaltopoulou T, Kastritis E, Terpos E and Dimopoulos MA: Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 21:167–179. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Richtsmeier WJ: Interferon-present and future prospects. Crit Rev Clin Lab Sci. 20:57–93. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JS and Shin EC: The type I interferon response in COVID-19: Implications for treatment. Nat Rev Immunol. 20:585–586. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, Péré H, Charbit B, Bondet V, Chenevier-Gobeaux C, et al: Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 369:718–724. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, et al: Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 9:196–206. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, Fazeli MR, Ghazaeian M and Yekaninejad MS: Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 88:1069032020. View Article : Google Scholar : PubMed/NCBI | |
|
Joseph BA, Dibas M, Evanson KW, Paranjape G, Vegivinti CTR, Selvan PT, Saravu K, Gupta N, Pulakurthi YS, Keesari PR, et al: Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review. Expert Rev Anti Infect Ther. 19:679–687. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Ma L, Zhuang Z, Cai S, Zhao Z, Zhou L, Zhang J, Wang PH, Zhao J and Cui J: Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling. Signal Transduct Target Ther. 5:2212020. View Article : Google Scholar : PubMed/NCBI | |
|
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al: A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 382:1787–1799. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Ma C, Szeto T, Hurst B, Tarbet B and Wang J: Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses. ACS Infect Dis. 7:586–597. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, et al: Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat Commun. 12:60552021. View Article : Google Scholar : PubMed/NCBI | |
|
Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, et al: Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta-analysis. Ann Med. 54:516–523. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Colson P, Rolain JM and Raoult D: Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 55:1059232020. View Article : Google Scholar : PubMed/NCBI | |
|
Cuadrado-Lavín A, Olmos JM, Cifrian JM, Gimenez T, Gandarillas MA, García-Saiz M, Rebollo MH, Martínez-Taboada V, López-Hoyos M, Fariñas MC and Crespo J: Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Trials. 21:4722020. View Article : Google Scholar : PubMed/NCBI | |
|
RECOVERY Collaborative Group, . Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, et al: Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 383:2030–2040. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al: Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 56:1059492020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, et al: The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 6:282020. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Liu R, Zhang R, Zhang S, Wei Y, Zhang L, Zhou H and Yang C: Protective effect of arbidol against pulmonary fibrosis and sepsis in mice. Front Pharmacol. 11:6070752020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Lu J and Xue Y: Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 81:e21–e23. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Song Y, Zhang M, Yin L, Wang K, Zhou Y, Zhou M and Lu Y: COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents. 56:1060802020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Timilsena YP, Blanch E and Adhikari B: Lactoferrin: Structure, function, denaturation and digestion. Crit Rev Food Sci Nutr. 59:580–596. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Meng X, Zhang F, Xiang Y and Wang J: The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg Microbes Infect. 10:317–330. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Salaris C, Scarpa M, Elli M, Bertolini A, Guglielmetti S, Pregliasco F, Blandizzi C, Brun P and Castagliuolo I: Protective effects of lactoferrin against SARS-CoV-2 infection in vitro. Nutrients. 13:3282021. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:271–280.e8. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tian L, Qiang T, Liang C, Ren X, Jia M, Zhang J, Li J, Wan M, YuWen X, Li H, et al: RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur J Med Chem. 213:1132012021. View Article : Google Scholar : PubMed/NCBI | |
|
Cao YC, Deng QX and Dai SX: Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 35:1016472020. View Article : Google Scholar : PubMed/NCBI | |
|
McDonald S, Turner S, Page MJ and Turner T: Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency. J Clin Epidemiol. 146:22–31. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, et al: Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 386:509–520. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Good SS, Westover J, Jung KH, Zhou XJ, Moussa A, La Colla P, Collu G, Canard B and Sommadossi JP: AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 65:e02479–20. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez MA: Plitidepsin: A repurposed drug for the treatment of COVID-19. Antimicrob Agents Chemother. 65:e00200–21. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, Jangra S, Uccellini MB, Rathnasinghe R, Coughlan L, et al: Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 371:926–931. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rodon J, Muñoz-Basagoiti J, Perez-Zsolt D, Noguera-Julian M, Paredes R, Mateu L, Quiñones C, Perez C, Erkizia I, Blanco I, et al: Identification of plitidepsin as potent inhibitor of SARS-CoV-2-induced cytopathic effect after a drug repurposing screen. Front Pharmacol. 12:6466762021. View Article : Google Scholar : PubMed/NCBI | |
|
Soto-Matos A, Szyldergemajn S, Extremera S, Miguel-Lillo B, Alfaro V, Coronado C, Lardelli P, Roy E, Corrado CS and Kahatt C: Plitidepsin has a safe cardiac profile: A comprehensive analysis. Mar Drugs. 9:1007–1023. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS and Reiersen AM: Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA. 324:2292–2300. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, Han MA, Sadeghirad B, Agarwal A, Agoritsas T, et al: Prophylaxis against covid-19: Living systematic review and network meta-analysis. BMJ. 373:n9492021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y and Wang Q: Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis. 71:2688–2694. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT, Wood C, Berrueta M, et al: Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 384:610–618. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Abolghasemi H, Eshghi P, Cheraghali AM, Imani Fooladi AA, Bolouki Moghaddam F, Imanizadeh S, Moeini Maleki M, Ranjkesh M, Rezapour M, Bahramifar A, et al: Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci. 59:1028752020. View Article : Google Scholar : PubMed/NCBI | |
|
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al: Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 323:1582–1589. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge DO, et al: Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 95:1888–1897. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cao W, Liu X, Bai T, Fan H, Hong K, Song H, Han Y, Lin L, Ruan L and Li T: High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 7:ofaa1022020. View Article : Google Scholar : PubMed/NCBI | |
|
Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, Han Y, Xiong Y, Liu Z, Ruan L and Li T: High-dose intravenous immunoglobulin in severe coronavirus disease 2019: A multicenter retrospective study in China. Front Immunol. 12:6278442021. View Article : Google Scholar : PubMed/NCBI | |
|
Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, Castaldo G and Bianco A: ACE2: The major cell entry receptor for SARS-CoV-2. Lung. 198:867–877. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, et al: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 584:120–124. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shepard HM, Phillips GL, D Thanos C and Feldmann M: Developments in therapy with monoclonal antibodies and related proteins. Clin Med (Lond). 17:220–232. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al: An mRNA vaccine against SARS-CoV-2-preliminary report. N Engl J Med. 383:1920–1931. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR and Jenkins G: Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 76:907–919. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, et al: Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19. JAMA Intern Med. 181:41–51. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, et al: REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 385:e812021. View Article : Google Scholar : PubMed/NCBI | |
|
O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, et al: Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 385:1184–1195. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ryu DK, Kang B, Noh H, Woo SJ, Lee MH, Nuijten PM, Kim JI, Seo JM, Kim C, Kim M, et al: The in vitro and in vivo efficacy of CT-P59 against gamma, delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 578:91–96. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N and Hagino O; Sarilumab COVID-19 Global Study Group, : Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 9:522–532. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Pang J, Xu F, Aondio G, Li Y, Fumagalli A, Lu M, Valmadre G, Wei J, Bian Y, Canesi M, et al: Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun. 12:8142021. View Article : Google Scholar : PubMed/NCBI | |
|
Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F and Focosi D: Anti-SARS-CoV-2 neutralizing monoclonal antibodies: Clinical pipeline. MAbs. 12:18541492020. View Article : Google Scholar : PubMed/NCBI | |
|
Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A, et al: SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 185:467–484.e15. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, et al: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 602:657–663. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Mannar D, Saville JW, Zhu X, Srivastava SS, Berezuk AM, Tuttle KS, Marquez AC, Sekirov I and Subramaniam S: SARS-CoV-2 omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science. 375:760–764. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Miller NL, Clark T, Raman R and Sasisekharan R: Insights on the mutational landscape of the SARS-CoV-2 omicron variant. bioRxiv. doi: 10.1101/2021.12.06.471499 (Preprint). | |
|
Shah M and Woo HG: Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies. Front Immunol. 12:8305272021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen RE, Winkler ES, Case JB, Aziati ID, Bricker TL, Joshi A, Darling TL, Ying B, Errico JM, Shrihari S, et al: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 596:103–108. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kakoulidis I, Ilias I and Koukkou E: SARS-CoV-2 infection and glucose homeostasis in pregnancy. What about antenatal corticosteroids? Diabetes Metab Syndr. 14:519–520. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Tedeschi S, Giannella M, Rinaldi M, Bussini L, Valentini I, Ferravante AF, et al: Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: A multicentre study. Clin Microbiol Infect. 27:105–111. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tang X, Feng YM, Ni JX, Zhang JY, Liu LM, Hu K, Wu XZ, Zhang JX, Chen JW, Zhang JC, et al: Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: A multicenter, single-blind, randomized control trial. Respiration. 100:116–126. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC and Arbous SM: Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Crit Care. 24:6962020. View Article : Google Scholar : PubMed/NCBI | |
|
So C, Ro S, Murakami M, Imai R and Jinta T: High-dose, short-term corticosteroids for ARDS caused by COVID-19: A case series. Respirol Case Rep. 8:e005962020. View Article : Google Scholar : PubMed/NCBI | |
|
Kolilekas L, Loverdos K, Giannakaki S, Vlassi L, Levounets A, Zervas E and Gaga M: Can steroids reverse the severe COVID-19 induced ‘cytokine storm’? J Med Virol. 92:2866–2869. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan M, Xu X, Xia D, Tao Z, Yin W, Tan W, Hu Y and Song C: Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: A propensity score-based analysis. Shock. 54:638–643. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X, Chen T, Wang Y, Wang J and Yan F: Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Crit Care. 24:2412020. View Article : Google Scholar : PubMed/NCBI | |
|
Rello J, Belliato M, Dimopoulos MA, Giamarellos-Bourboulis EJ, Jaksic V, Martin-Loeches I, Mporas I, Pelosi P, Poulakou G, Pournaras S, et al: Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesth Crit Care Pain Med. 39:723–730. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lentz S, Roginski MA, Montrief T, Ramzy M, Gottlieb M and Long B: Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS. Am J Emerg Med. 38:2194–2202. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wong DJN, El-Boghdadly K, Owen R, Johnstone C, Neuman MD, Andruszkiewicz P, Baker PA, Biccard BM, Bryson GL, Chan MTV, et al: Emergency airway management in patients with COVID-19: A prospective international multicenter cohort study. Anesthesiology. 135:292–303. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A and Higgs A: Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the difficult airway society, the association of anaesthetists the intensive care society, the faculty of intensive care medicine and the royal college of anaesthetists. Anaesthesia. 75:785–799. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M and Merouani K: High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 18:1743–1746. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ronco C, Reis T and Husain-Syed F: Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 8:738–742. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ronco C, Bagshaw SM, Bellomo R, Clark WR, Husain-Syed F, Kellum JA, Ricci Z, Rimmelé T, Reis T and Ostermann M: Extracorporeal blood purification and organ support in the critically Ill patient during COVID-19 Pandemic: expert review and recommendation. Blood Purif. 50:17–27. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D and Singh S: Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: Immunological mechanisms, clinical manifestations and management. Rheumatol Int. 41:19–32. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Megyeri K, Dernovics Á, Al-Luhaibi ZII and Rosztóczy A: COVID-19-associated diarrhea. World J Gastroenterol. 27:3208–3222. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lu ZH, Yang CL, Yang GG, Pan WX, Tian LG, Zheng JX, Lv S, Zhang SY, Zheng PY and Zhang SX: Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: A randomized multicenter trial. Infect Dis Poverty. 10:312021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Li Y, Zhou L, Zhou X, Xie B, Zhang W and Sun J: Prevention and treatment of COVID-19 using traditional Chinese medicine: A review. Phytomedicine. 85:1533082021. View Article : Google Scholar : PubMed/NCBI | |
|
Ren JL, Zhang AH and Wang XJ: Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res. 155:1047432020. View Article : Google Scholar : PubMed/NCBI | |
|
Ni L, Chen L, Huang X, Han C, Xu J, Zhang H, Luan X, Zhao Y, Xu J, Yuan W and Chen H: Combating COVID-19 with integrated traditional Chinese and western medicine in China. Acta Pharm Sin B. 10:1149–1162. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Anand U, Jakhmola S, Indari O, Jha HC, Chen ZS, Tripathi V and Pérez de la Lastra JM: Potential therapeutic targets and vaccine development for SARS-CoV-2/COVID-19 pandemic management: A review on the recent update. Front Immunol. 12:6585192021. View Article : Google Scholar : PubMed/NCBI | |
|
Tregoning JS, Flight KE, Higham SL, Wang Z and Pierce BF: Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 21:626–636. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hou Z, Tong Y, Du F, Lu L, Zhao S, Yu K, Piatek SJ, Larson HJ and Lin L: Assessing COVID-19 vaccine hesitancy, confidence, and public engagement: A global social listening study. J Med Internet Res. 23:e276322021. View Article : Google Scholar : PubMed/NCBI | |
|
Sharif N, Alzahrani KJ, Ahmed SN and Dey SK: Efficacy, immunogenicity and safety of COVID-19 vaccines: A systematic review and meta-analysis. Front Immunol. 12:7141702021. View Article : Google Scholar : PubMed/NCBI | |
|
Francis AI, Ghany S, Gilkes T and Umakanthan S: Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 98:389–394. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Canedo-Marroquín G, Saavedra F, Andrade CA, Berrios RV, Rodríguez-Guilarte L, Opazo MC, Riedel CA and Kalergis AM: SARS-CoV-2: Immune response elicited by infection and development of vaccines and treatments. Front Immunol. 11:5697602020. View Article : Google Scholar : PubMed/NCBI | |
|
Rauch S, Roth N, Schwendt K, Fotin-Mleczek M, Mueller SO and Petsch B: mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines. 6:572021. View Article : Google Scholar : PubMed/NCBI | |
|
Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, et al: Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): A randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 22:329–340. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, Bern H, O'Hara J, McFarlane LR, Lemm NM, et al: Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinical Medicine. 44:1012622022. View Article : Google Scholar : PubMed/NCBI | |
|
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, et al: Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA. 326:35–45. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, Lye DC, Lee VJ and Tan KB: Comparative effectiveness of mRNA and inactivated whole virus vaccines against COVID-19 infection and severe disease in Singapore. Clin Infect Dis. Apr 12–2022.(Epub ahead of print). PubMed/NCBI | |
|
Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, Cortes FH, Grifoni A, Tarke A, Chang J, et al: Humoral and cellular immune memory to four COVID-19 vaccines. bioRxiv. doi: 10.1101/2022.03.18.484953 (Preprint). | |
|
Islam N, Sheils NE, Jarvis MS and Cohen K: Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nat Commun. 13:23772022. View Article : Google Scholar : PubMed/NCBI | |
|
Mohamed K, Rzymski P, Islam MS, Makuku R, Mushtaq A, Khan A, Ivanovska M, Makka SA, Hashem F, Marquez L, et al: COVID-19 vaccinations: The unknowns, challenges, and hopes. J Med Virol. 94:1336–1349. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zhang X, Liu J, Xia H, Zou J, Muruato AE, Periasamy S, Plante JA, Bopp NE, Kurhade C, et al: A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. bioRxiv. 2022.02.14.480460. 2022. | |
|
Merzon E, Green I, Somekh E, Vinker S, Golan-Cohen A, Israel A, Gorohovski A, Frenkel-Morgenstern M and Stein M: The association of previous vaccination with live-attenuated varicella zoster vaccine and COVID-19 positivity: An Israeli population-based study. Vaccines (Basel). 10:742022. View Article : Google Scholar : PubMed/NCBI | |
|
Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J and Clemens R: Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 397:682–694. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, et al: Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 21:1107–1119. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Jin P, Guo X, Chen W, Ma S, Pan H, Dai L, Du P, Wang L, Jin L, Chen Y, et al: Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS Med. 19:e10039532022. View Article : Google Scholar : PubMed/NCBI | |
|
Kuhn M, Campillos M, Letunic I, Jensen LJ and Bork P: A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 6:3432010. View Article : Google Scholar : PubMed/NCBI | |
|
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, et al: Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: A prospective observational study. Lancet Infect Dis. 21:939–949. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Vetter V, Denizer G, Friedland LR, Krishnan J and Shapiro M: Understanding modern-day vaccines: What you need to know. Ann Med. 50:110–120. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Akinosoglou K, Tzivaki I and Marangos M: Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon. Clin Immunol. 226:1087212021. View Article : Google Scholar : PubMed/NCBI | |
|
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 384:403–416. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y and Balicer RD: SARS-CoV-2 breakthrough infections in vaccinated individuals: Measurement, causes and impact. Nat Rev Immunol. 22:57–65. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D, Stuart DI, et al: Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 399:234–236. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, Sabo RT, Hall N, Foreman A, Schubert PL, et al: Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings-barnstable county, massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 70:1059–1062. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tay MZ, Wiehe K and Pollara J: Antibody-dependent cellular phagocytosis in antiviral immune responses. Front Immunol. 10:3322019. View Article : Google Scholar : PubMed/NCBI | |
|
Forni G and Mantovani A; COVID-19 Commission of Accademia Nazionale dei Lincei Rome, : COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ. 28:626–639. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bagheri A, Moezzi SMI, Mosaddeghi P, Nadimi Parashkouhi S, Fazel Hoseini SM, Badakhshan F and Negahdaripour M: Interferon-inducer antivirals: Potential candidates to combat COVID-19. Int Immunopharmacol. 91:1072452021. View Article : Google Scholar : PubMed/NCBI | |
|
Cáceres CJ, Cardenas-Garcia S, Carnaccini S, Seibert B, Rajao DS, Wang J and Perez DR: Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci Rep. 11:96092021. View Article : Google Scholar : PubMed/NCBI | |
|
Heilmann E, Costacurta F, Geley S, Mogadashi SA, Volland A, Rupp B, Harris RS and von Laer D: A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Commun Biol. 5:3912022. View Article : Google Scholar : PubMed/NCBI | |
|
Mahase E: Covid-19: Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 375:n27132021. View Article : Google Scholar : PubMed/NCBI | |
|
Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, Dehghan N, Navaei M and Ranjbar M: Effect of arbidol (Umifenovir) on COVID-19: A randomized controlled trial. BMC Infect Dis. 20:9542020. View Article : Google Scholar : PubMed/NCBI | |
|
Chang R, Ng TB and Sun WZ: Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents. 56:1061182020. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, Søgaard OS, Hasselstrøm JB, Winkler M, Hempel T, et al: Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 65:1032552021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, et al: Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 395:1569–1578. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF and Tandon M: Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Diss. 103:62–71. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Şimşek-Yavuz S and Komsuoğlu Çelikyurt FI: An update of anti-viral treatment of COVID-19. Turk J Med Sci. 51:3372–3390. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wood EM, Estcourt LJ and McQuilten ZK: How should we use convalescent plasma therapies for the management of COVID-19? Blood. 137:1573–1581. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt F, Weisblum Y, Rutkowska M, Poston D, DaSilva J, Zhang F, Bednarski E, Cho A, Schaefer-Babajew DJ, Gaebler C, et al: High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature. 600:512–516. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Case JB, Chen RE, Cao L, Ying B, Winkler ES, Johnson M, Goreshnik I, Pham MN, Shrihari S, Kafai NM, et al: Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host Microbe. 29:1151–1161.e5. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Guo K, Wustoni S, Koklu A, Díaz-Galicia E, Moser M, Hama A, Alqahtani AA, Ahmad AN, Alhamlan FS, Shuaib M, et al: Rapid single-molecule detection of COVID-19 and MERS antigens via nanobody-functionalized organic electrochemical transistors. Nat Biomed Eng. 5:666–677. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, et al: Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 383:2333–2344. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott N, et al: Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 385:1941–1950. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 384:229–237. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JY, Jang YR, Hong JH, Jung JG, Park JH, Streinu-Cercel A, Streinu-Cercel A, Săndulescu O, Lee SJ, Kim SH, et al: Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: Two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection. Clin Ther. 43:1706–1727. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, et al: Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med. 386:2188–2200. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, : Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): A randomised controlled trial. Lancet Infect Dis. 22:622–635. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, et al: REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 384:238–251. 2021. View Article : Google Scholar : PubMed/NCBI |
